Redefining Adnexal Mass Management with Precise Care
Complementing your adnexal mass protocol, OvaWatch® and Ova1Plus® offer an individualized approach to risk assessment, to help ensure the right patient receives the right treatment at the right time.
Our OvaSuiteSM Portfolio of Products
Our non-invasive blood tests offers precise tools to inform ovarian care, helping providers enhance confidence in their medical management plans and triage specialist referrals more efficiently.
Planned for Clinical Management
- For adnexal masses initially evaluated as indeterminate or benign
- Negative Predictive Value of over 99%1
- Longitudinal monitoring feature to help providers track risk over time
Planned for Surgical Management
- For adnexal masses that are planned for surgery
- Ova1® has a greater than 96% sensitivity with clinical assessment2
- Biomarkers (including CA-125), menopausal status, and ultrasound for a personalized risk score
Ova1Plus is a reflex process: Ova1® is performed3 first. If an intermediate risk is detected, Overa® is automatically performed.
Watch This Video to Learn Which Test Is Best for Your Patient
How It Works
Our Services
Price Transparency & Financial Assistance to Patients
We are committed to making tests available to all women who need them. Covered by Medicare, Medicaid, and commercial insurance in many states. Cash pay is $295 per test. Financial assistance and payment plans are available for qualifying patients.
PRECAUTION:
OVAWATCH IS INTENDED FOR USE AS A NON-INVASIVE TEST TO ASSESS THE RISK OF OVARIAN CANCER FOR WOMEN WITH ADNEXAL MASSES, EVALUATED BY INITIAL CLINICAL ASSESSMENT (ICA) AS INDETERMINATE OR BENIGN. IN CONJUNCTION WITH IMAGING (ULTRASOUND AND/OR CT) AND CLINICAL ASSESSMENT, THIS TEST WILL SUPPORT PHYSICIANS IN MAKING INFORMED CLINICAL DECISIONS IN THE MANAGEMENT OF WOMEN WITH ADNEXAL MASSES. THE TEST IS NOT INTENDED AS A SCREENING TEST OR A STAND-ALONE DIAGNOSTIC ASSAY.
OVA1 AND OVERA SHOULD NOT BE USED WITHOUT AN INDEPENDENT CLINICAL AND IMAGING EVALUATION AND IS NOT INTENDED TO BE A SCREENING TEST OR TO DETERMINE WHETHER A PATIENT SHOULD PROCEED TO SURGERY. INCORRECT USE CARRIES THE RISK OF UNNECESSARY TESTING, SURGERY, AND/OR DELAYED DIAGNOSIS.